title: Analysis of the networks controlling the antimicrobial-peptide-dependent induction of Klebsiella pneumoniae virulence factors.
abstract: Antimicrobial peptides (APs) impose a threat to the survival of pathogens, and it is reasonable to postulate that bacteria have developed strategies to counteract them. Polymyxins are becoming the last resort to treat infections caused by multidrug-resistant Gram-negative bacteria and, similar to APs, they interact with the anionic lipopolysaccharide. Given that polymyxins and APs share the initial target, it is possible that bacterial defense mechanisms against polymyxins will be also effective against host APs. We sought to determine whether exposure to polymyxin will increase Klebsiella pneumoniae resistance to host APs. Indeed, exposure of K. pneumoniae to polymyxin induces cross-resistance not only to polymyxin itself but also to APs present in the airways. Polymyxin treatment upregulates the expression of the capsule polysaccharide operon and the loci required to modify the lipid A with aminoarabinose and palmitate with a concomitant increase in capsule and lipid A species containing such modifications. Moreover, these surface changes contribute to APs resistance and also to polymyxin-induced cross-resistance to APs. Bacterial loads of lipid A mutants in trachea and lungs of intranasally infected mice were lower than those of wild-type strain. PhoPQ, PmrAB, and the Rcs system govern polymyxin-induced transcriptional changes, and there is a cross talk between PhoPQ and the Rcs system. Our findings support the notion that Klebsiella activates a defense program against APs that is controlled by three signaling systems. Therapeutic strategies directed to prevent the activation of this program could be a new approach worth exploring to facilitate the clearance of the pathogen from the airways.
authors.affiliation: Laboratory Microbial Pathogenesis, Fundació d'Investigació Sanitària de les Illes Balears, Recinto Hospital Joan March, Carretera Soller Km 12, 07110 Bunyola, Spain.
authors.forename: Enrique
authors.initials: E
authors.lastname: Llobet
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Campos
authors.forename: Paloma
authors.initials: P
authors.lastname: Giménez
authors.forename: David
authors.initials: D
authors.lastname: Moranta
authors.forename: José A
authors.initials: JA
authors.lastname: Bengoechea
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D023181:Antimicrobial Cationic Peptides / Q000494:pharmacology*; D001089:Arabinose / Q000031:analogs & derivatives / Q000378:metabolism; D016667:Bacterial Capsules / Q000096:biosynthesis / Q000235:genetics; D058491:Bacterial Load; D001426:Bacterial Proteins / Q000378:metabolism*; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D007710:Klebsiella Infections / Q000382:microbiology*; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000378:metabolism / Q000472:pathogenicity*; D008050:Lipid A / Q000032:analysis; D008168:Lung / Q000382:microbiology; D013058:Mass Spectrometry; D051379:Mice; D008810:Mice, Inbred C57BL; D008826:Microbial Sensitivity Tests; D019308:Palmitic Acid / Q000032:analysis; D011113:Polymyxins / Q000494:pharmacology*; D014132:Trachea / Q000382:microbiology; D037521:Virulence Factors / Q000096:biosynthesis
chemical_list: D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D001426:Bacterial Proteins; D008050:Lipid A; D011113:Polymyxins; D037521:Virulence Factors; C016982:aminoarabinose; D019308:Palmitic Acid; D001089:Arabinose